New cocktail aims to wipe out prostate cancer before surgery
NCT ID NCT07516704
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding two drugs (darolutamide and homoharringtonine) to standard chemo and hormone therapy can more thoroughly clear high-risk prostate cancer before surgery. About 94 men will receive the combo for 7 weeks, then have their prostate removed to check for remaining cancer. The goal is to see if this approach leads to a complete or near-complete response in the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel, darolutamide, homoharringtonine, and androgen deprivation therapy
What this could lead to
If successful, this could point toward a more effective pre-surgery treatment for high-risk prostate cancer, potentially improving long-term outcomes.
What could go wrong
This is a very early, small trial (94 people) with no control group, so results may not be conclusive. The drug combination also carries risks like infection, fatigue, and bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••